Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia.
James SunXiaojun ZhongJunjie MaWeihong SunHyo S HanHatem H SolimanLoretta S LoftusRicardo L B CostaAvan J ArmaghaniAixa E Soyano-MullerBrian J CzernieckiM Catherine LeeJohn V KilukNazanin KhakpourSusan J HooverChristine LarongaHung T KhongPublished in: Cancer medicine (2021)
The effectiveness of palbociclib and endocrine therapy in the treatment of HR-positive, HER2-negative mBC in the real-world setting is similar to the efficacy reported in the PALOMA-2 trial. Patients with lower neutrophil count may have a lower risk of early disease progression.